Organon & Co. (OGN) Stock Price, Quote & News

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 551 430 6900

Website: www.organon.com

Address:

30 Hudson Street, Floor 33, Jersey City, United States

BOBJOSCAUWBERGH Nov. 12 at 4:56 PM

$OGN if we get above 7.77 we fill the gap to around 9

0 · Reply

JarvisFlow Nov. 11 at 4:09 PM

JP Morgan has adjusted their stance on Organon ( $OGN ), setting the rating to Underweight with a target price of 14 → 12.

0 · Reply

JarvisFlow Nov. 11 at 12:35 PM

Morgan Stanley updates rating for Organon ( $OGN ) to Equal-Weight, target set at 10 → 9.

0 · Reply

epetes Nov. 11 at 12:10 AM

$OGN I sold at 7.75 today for an excellent 2 week profit from 6.50. I set a limit to buy back at 7.35 and ride it up again.

0 · Reply

GSP Nov. 11 at 12:10 AM

$SPY $SNAP $LWLG $OGN $ASST

0 · Reply

BearTamerTrading Nov. 10 at 4:44 PM

🚀 Premarket Power Plays — Bear Tamer Trading Community Wins 🔥 Part 2/3 The following plays were called LIVE during premarket before the crowd: 🔥 $GLTO — 323% move off cell-therapy data re-rating/press release 🔥 $OGN — Broad Women’s Health spin-out momentum & product update 🔥 $IPHA — Pipeline progress announcement in dermatology/auto-immune space 🔥 $RUM — Video-platform commentary surge & speculative breakout play. Members were already in position before the volume spike 💪 If you missed it, watch the replay for proof — testimonials are in the comments ⬇️ 🎥 Replay Link: https://www.youtube.com/live/vlYDstPoN2w?si=sy_JgV1cEZVx78Vf

4 · Reply

cadence_fx Nov. 10 at 4:43 PM

$OGN The United Kingdom is open for Mainz Biomed after MHRA registration on September 2, 2025 and a London lab partner. The serviceable population is about 34.6 million adults above 50. Scale is already baked in 📈

0 · Reply

d_risk Nov. 10 at 4:16 PM

$OGN - Organon & Co. Common Stock - 10Q - Updated Risk Factors OGN flags costly internal audit probe, heightened risks from reliance on key products amid regulatory, competitive, and market pressures, and warns that new drug pricing reforms could materially impact results. #Pharmaceuticals #MarketCompetition #DrugPricingReform #ProductConcentration #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/OGN/10-Q/2025-11-10

0 · Reply

GuruRanger Nov. 10 at 2:56 PM

$OGN Flying below everybody's radar. Someday this will get picked up.

1 · Reply

frankster Nov. 10 at 2:25 PM

$OGN why not allocate $100-200m to stock buyback to clear out the shorts. it’s mispriced but market doesn’t care

1 · Reply

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Nov 11, 2025, 11:40 AM EST - 3 days ago

Organon Analysts Cut Their Forecasts Following Q3 Results

Nov 10, 2025, 10:51 AM EST - 4 days ago

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 7:30 AM EST - 4 days ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 7, 2025, 7:30 AM EST - 7 days ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 6, 2025, 7:30 AM EST - 8 days ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Oct 28, 2025, 2:06 PM EDT - 17 days ago

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Oct 27, 2025, 6:22 PM EDT - 18 days ago

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Oct 27, 2025, 7:44 AM EDT - 18 days ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:30 AM EDT - 18 days ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 17, 2025, 7:10 AM EDT - 4 weeks ago

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Sep 19, 2025, 6:00 AM EDT - 2 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 2 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Aug 12, 2025, 2:22 PM EDT - 3 months ago

Organon: Valuation Discount Offset By Structural Headwinds

Aug 6, 2025, 11:59 AM EDT - 3 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 5, 2025, 1:10 PM EDT - 3 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:30 AM EDT - 3 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Jul 22, 2025, 7:30 AM EDT - 4 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 21, 2025, 4:02 PM EDT - 4 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 20, 2025, 10:55 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 10, 2025, 8:18 AM EDT - 4 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 8, 2025, 1:14 PM EDT - 4 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Jul 7, 2025, 7:30 AM EDT - 4 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 3, 2025, 8:25 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 1:00 AM EDT - 4 months ago

Karolinska Development receives update from Organon concerning OG-6219

Jul 2, 2025, 8:01 AM EDT - 4 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 7:30 AM EDT - 4 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jun 28, 2025, 7:46 AM EDT - 4 months ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 26, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 20, 2025, 9:06 AM EDT - 5 months ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 18, 2025, 8:38 AM EDT - 5 months ago

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Jun 18, 2025, 1:02 AM EDT - 5 months ago

Organon: A Look Beyond The Dividend Cut

Jun 16, 2025, 8:18 AM EDT - 5 months ago

OGN SHAREHOLDER REPORT: Organon & Co. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

BOBJOSCAUWBERGH Nov. 12 at 4:56 PM

$OGN if we get above 7.77 we fill the gap to around 9

0 · Reply

JarvisFlow Nov. 11 at 4:09 PM

JP Morgan has adjusted their stance on Organon ( $OGN ), setting the rating to Underweight with a target price of 14 → 12.

0 · Reply

JarvisFlow Nov. 11 at 12:35 PM

Morgan Stanley updates rating for Organon ( $OGN ) to Equal-Weight, target set at 10 → 9.

0 · Reply

epetes Nov. 11 at 12:10 AM

$OGN I sold at 7.75 today for an excellent 2 week profit from 6.50. I set a limit to buy back at 7.35 and ride it up again.

0 · Reply

GSP Nov. 11 at 12:10 AM

$SPY $SNAP $LWLG $OGN $ASST

0 · Reply

BearTamerTrading Nov. 10 at 4:44 PM

4 · Reply

cadence_fx Nov. 10 at 4:43 PM

0 · Reply

d_risk Nov. 10 at 4:16 PM

0 · Reply

GuruRanger Nov. 10 at 2:56 PM

$OGN Flying below everybody's radar. Someday this will get picked up.

1 · Reply

frankster Nov. 10 at 2:25 PM

$OGN why not allocate $100-200m to stock buyback to clear out the shorts. it’s mispriced but market doesn’t care

1 · Reply

BOBJOSCAUWBERGH Nov. 10 at 1:08 PM

$OGN Organon's price-to-earnings (PE) ratio is around 2.5–3.4, far below the pharma industry average. Most large pharmaceutical peers, such as Pfizer and Novartis, trade at PE ratios of 17 to 29, with a sector median around 23–24. If Organon were valued even at the lower end of its peer group PE ratios (e.g., PE of 15), and with a trailing 12-month EPS of about $2.70–2.90, the fair price would be: $40.50 per share as a hypothetical fair value. At an ultra-conservative “distressed” PE of 7 (still much higher than 2.5), OGN would trade near $18.90.

1 · Reply

DonCorleone77 Nov. 10 at 1:02 PM

$OGN Organon reports Q3 adjusted EPS $1.01, consensus 93c -- Q3 revenue $1.6B, consensus $1.58B. -- Cuts FY25 revenue view to $6.2B-$6.25B from $6.28B-$6.38B , consensus $6.29B. -- Narrows FY25 adjusted EBITDA margin view to 31% from 31%-32%.

0 · Reply

AStrokeOfLuck Nov. 10 at 12:35 PM

$OGN

0 · Reply

AlertsAndNews Nov. 9 at 11:51 PM

$OGN Organon Reports Positive Phase 3 Sub-Analysis Showing VTAMA Cream Improves Atopic Dermatitis in Children Organon announced results from a sub-analysis of pooled Phase 3 ADORING 1 and ADORING 2 trials showing VTAMA cream produced early and clinically meaningful improvements in children aged 2–17 with atopic dermatitis. At week 8, patients showed significant gains in vIGA-AD™, EASI-75, POEM, and PP-NRS scores, indicating improvements in skin clearance, severity, and itch regardless of comorbidity status.

0 · Reply

OptionSamurai Nov. 7 at 4:00 PM

A new candidate for a wheel strategy on our screener: $OGN You can sell a put strike 5.0 (3.4 ATRs away) for 21-Nov-25. Return is 1.0% and 25.9% annualized. ✔ Breakeven is 23.8% away ✔ Dividend yield if assigned is 3.8% ✔ Annualized covered call return is 64.3% 💵 Company has a fundamental score of 9 and a growth score of 6 📈 IV percentile is 88.1% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP

1 · Reply

CDMO Nov. 7 at 12:41 PM

$OGN thats actually a smart move by them at this price

1 · Reply

AdLucrum Nov. 7 at 12:36 PM

$OGN Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

0 · Reply

559bigballz Nov. 6 at 8:50 PM

$OGN let’s goooo

1 · Reply

NoSirNoWay Nov. 6 at 6:13 PM

$OGN There is some hesitation. I like it but a lot of things are "on discount" right now.

2 · Reply

Value1996 Nov. 6 at 3:02 PM

$OGN locked in to report earnings before market opens 10th of November. Ready for some bullish results 😎

0 · Reply

handmedown1 Nov. 6 at 12:56 PM

$OGN interesting kvue got picked up and OGN is only accuaed of asking whosalers to take more inventory. They still have sales.

0 · Reply

MrNotSoNice Nov. 5 at 9:33 PM

$OGN Is this going to have a PE of 1? 🙄💊

0 · Reply

Market Cap	1.98B
Revenue (ttm)	6.40B
Net Income (ttm)	864.00M
EPS (ttm)	N/A
PE Ratio	2.11
Forward PE	2.10
Profit Margin	13.49%
Debt to Equity Ratio	12.14

Volume	7,124,600
Avg Vol	5,811,852
Day's Range	N/A - N/A
Shares Out	259.98M
Stochastic %K	77%
Beta	0.59
Analysts	Hold
Price Target	$10.33